D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
CRSP holding history
CRISPR Therapeutics AG in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CRSP overviewAll 13F holders of CRSPFull Q2 2026 holdings
- Shares (Q2 2026)
- 893,812
- Value
- $48.7M
- % of portfolio
- <0.1%
- Quarters held
- 12
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 893,812 | $48.7M | <0.1% | +893,812 | New | Holders |
| Q4 2024 | 0 | $0 | 0.0% | −29,365−100.0% | Sold out | Holders |
| Q3 2024 | 29,365 | $1.38M | <0.1% | +1,191+4.2% | Added | Holders |
| Q2 2024 | 28,174 | $1.52M | <0.1% | −146,121−83.8% | Reduced | Holders |
| Q1 2024 | 174,295 | $11.9M | <0.1% | +137,023+367.6% | Added | Holders |
| Q4 2023 | 37,272 | $2.33M | <0.1% | +37,272 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −4,600−100.0% | Sold out | Holders |
| Q1 2023 | 4,600 | $208.1K | <0.1% | −9,300−66.9% | Reduced | Holders |
| Q4 2022 | 13,900 | $565.0K | <0.1% | +13,900 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −37,620−100.0% | Sold out | Holders |
| Q1 2022 | 37,620 | $2.36M | <0.1% | +14,448+62.4% | Added | Holders |
| Q4 2021 | 23,172 | $1.76M | <0.1% | −11,524−33.2% | Reduced | Holders |
| Q3 2021 | 34,696 | $3.88M | <0.1% | +9,798+39.4% | Added | Holders |
| Q2 2021 | 24,898 | $4.03M | <0.1% | −52,294−67.7% | Reduced | Holders |
| Q1 2021 | 77,192 | $9.41M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.